Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-335 and Simvastatin Combination vs Monotherapy in Mixed Dyslipidemia
NCT00300456Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Mar 2006
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenofibric acid in mixed dyslipidemia (6 arms), sponsored by Abbott Laboratories. Primary endpoints: Mean Percent Change in Triglycerides at 12 weeks, Mean Percent Change in High-density Lipoprotein Cholesterol at 12 weeks and 1 more. Started Mar 2006; status: completed.
02
Drugs
fenofibric acid
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT00300456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300456.